Mutations in Ras genes (HRAS, KRAS, and NRAS) are among the most common oncogenic alterations in human cancers. Oncogenic Ras mutations often lead to constitutive activation of Ras proteins, promoting uncontrolled cell proliferation and survival. Recent studies have shown that dimerization of mutant Ras proteins can enhance their ability to activate downstream signaling pathways, thereby contributing to tumor progression and resistance to therapies.
